It is likely that the occurrence of antibiotic resistance in organisms that cause VAP will outstrip the ability of pharmaceutical manufacturers to develop new antibiotics active against these organisms. Bacteria can pass resistance mechanisms from one genus to another, and their rapid rate of multiplication allows for evolution of new resistance mechanisms within months of the first use of new antibiotics. These facts underscore the importance of prevention of inappropriate antibiotic use and the transfer of resistant organisms from one patient to another. Use of these strategies may be the only way to prevent a return to an era in which patients die because of the lack of availability of antibiotic therapy.
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine